Ischemic bowel disease, also known as ischemic bowel disease (IBD), is a type of disease that causes the blood supply to a certain intestinal segment to be reduced or stopped by various reasons such as hypovolemia, shock or recent abdominal surgery, resulting in insufficient blood supply to the intestinal wall, and causing a series of pathological changes in the intestine. Human umbilical cord blood mononuclear cells (HUCB-MNC) can be economically and conveniently isolated from human cord blood. The HUCB-MNC obtained from the isolation of human umbilical cord blood contains a variety of stem cells, such as hematopoietic stem cells, endothelial stem cells, etc. A number of previous studies have confirmed that HUCB-MNC can improve the occurrence of ischemic bowel disease through immunomodulatory and tissue repair. These characteristics make HUCB-MNC a cell with great potential to treat ischemic diseases.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Intravenous infusion of cord blood mononuclear cells
HongLi Yang
Jinan, Shandong, China
RECRUITINGConcentration of IL-8 in serum
Ischemic bowel disease increases the expression of IL-8.
Time frame: Compare the changes of 1 month, 3 months, 6 months and one year before treatment (baseline) and after
Concentration of NF-Kβ in serum
In the development of ischemic bowel disease, NFKβ activates the associated signaling pathway to exert an anti-inflammatory effect.
Time frame: Compare the changes of 1 month, 3 months, 6 months and one year before treatment (baseline) and after
Concentration of IL-6 in serum
Ischemic bowel disease increases the expression of IL-6.
Time frame: Compare the changes of 1 month, 3 months, 6 months and one year before treatment (baseline) and after
Concentration of IL-1β in serum
Ischemic bowel disease increases the expression of IL-1β.
Time frame: Compare the changes of 1 month, 3 months, 6 months and one year before treatment (baseline) and after
Concentration of Nrf2 in serum
In the development of ischemic bowel disease, Nrf2 interacts with NF-Kβ and has an anti-inflammatory effect.
Time frame: Compare the changes of 1 month, 3 months, 6 months and one year before treatment (baseline) and after
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.